Immunesensor Therapeutics

ImmuneSensor Therapeutics is a clinical-stage biotechnology company located in Dallas, Texas, focused on developing innovative therapies that target the cGAS-STING pathway to modulate the innate immune system. With a commitment to addressing inflammatory and autoimmune diseases, the company is pioneering best-in-class cGAS inhibitors based on significant research by Dr. Zhijian James Chen, a recipient of the 2024 Lasker Basic Medical Research Award.

Since the discovery of the cGAS enzyme and its secondary messenger cGAMP in 2012, ImmuneSensor has been at the forefront of leveraging this critical pathway to develop therapeutic solutions. The company's unique approach aims to suppress inflammation and autoimmunity in patients whose immune systems are overactive, recognizing the broad applicability of the cGAS-STING pathway in various therapeutic areas.

Generated from the website